Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2022 2
2023 3
2024 4
2025 4

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

11 results

Results by year

Filters applied: . Clear all
Page 1
Cancer therapy with antibodies.
Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Wright KM, Gabelli SB, Ho M, van Elsas A, Zhou S. Paul S, et al. Nat Rev Cancer. 2024 Jun;24(6):399-426. doi: 10.1038/s41568-024-00690-x. Epub 2024 May 13. Nat Rev Cancer. 2024. PMID: 38740967 Free PMC article. Review.
TRBC1-targeting antibody-drug conjugates for the treatment of T cell cancers.
Nichakawade TD, Ge J, Mog BJ, Lee BS, Pearlman AH, Hwang MS, DiNapoli SR, Wyhs N, Marcou N, Glavaris S, Konig MF, Gabelli SB, Watson E, Sterling C, Wagner-Johnston N, Rozati S, Swinnen L, Fuchs E, Pardoll DM, Gabrielson K, Papadopoulos N, Bettegowda C, Kinzler KW, Zhou S, Sur S, Vogelstein B, Paul S. Nichakawade TD, et al. Nature. 2024 Apr;628(8007):416-423. doi: 10.1038/s41586-024-07233-2. Epub 2024 Mar 27. Nature. 2024. PMID: 38538786 Free PMC article.
Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities.
Mog BJ, Marcou N, DiNapoli SR, Pearlman AH, Nichakawade TD, Hwang MS, Douglass J, Hsiue EH, Glavaris S, Wright KM, Konig MF, Paul S, Wyhs N, Ge J, Miller MS, Azurmendi P, Watson E, Pardoll DM, Gabelli SB, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S. Mog BJ, et al. Sci Transl Med. 2024 Jul 10;16(755):eadg7123. doi: 10.1126/scitranslmed.adg7123. Epub 2024 Jul 10. Sci Transl Med. 2024. PMID: 38985855
Allogeneic Blood or Marrow Transplantation with Post-Transplantation Cyclophosphamide for Peripheral T Cell Lymphoma: The Importance of Graft Source.
Sterling CH, Hughes MS, Tsai HL, Yarkony K, Fuchs EJ, Swinnen LJ, Paul S, Bolaños-Meade J, Luznik L, Imus PH, Ali SA, Jain T, Ambinder A, DeZern A, Huff CA, Gocke CB, Varadhan R, Wagner-Johnston N, Jones RJ, Ambinder RF. Sterling CH, et al. Transplant Cell Ther. 2023 Apr;29(4):267.e1-267.e5. doi: 10.1016/j.jtct.2022.12.009. Epub 2022 Dec 19. Transplant Cell Ther. 2023. PMID: 36549386 Free PMC article. Review.
Hydrophobic interactions dominate the recognition of a KRAS G12V neoantigen.
Wright KM, DiNapoli SR, Miller MS, Aitana Azurmendi P, Zhao X, Yu Z, Chakrabarti M, Shi W, Douglass J, Hwang MS, Hsiue EH, Mog BJ, Pearlman AH, Paul S, Konig MF, Pardoll DM, Bettegowda C, Papadopoulos N, Kinzler KW, Vogelstein B, Zhou S, Gabelli SB. Wright KM, et al. Nat Commun. 2023 Aug 21;14(1):5063. doi: 10.1038/s41467-023-40821-w. Nat Commun. 2023. PMID: 37604828 Free PMC article.
11 results